Article
Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors
3 Sept 2024
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
